For Clinicians

Studies Continue to Support the Therapeutic Method of the TAMP™ Platform for Targeted Treatment of Pancreatic Cancer

Following are highlights of clinical data from publications, abstracts, and medical conference presentations.^*

Advances in Pancreatic Cancer: Trans-arterial Therapy Presented at Symposium on Clinical Interventional Oncology (CIO)

World Congress on Gastrointestinal Cancer - Celebrating 25 Years

The Phase 3 Study: Targeted Intra-Arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel Following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC) First Interim Analysis Presented at the 2023 ESMO World Congress on Gastrointestinal Cancer

Open-Label Phase-III TIGeR-PaC Interim Data Observes-6-Month Median Survival Benefit – third installment

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: Video 3 Presented on OncologyTube 2023

RenovoGem

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC) – Phase III Trial Interim Analysis Presented at the 2023 AACR Annual Meeting

Open-Label Phase-III TIGeR-PaC Interim Data Observes-6-Month Median Survival Benefit – second installment

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: Video 2 Presented on OncologyTube 2023

Open-Label Phase-III TIGeR-PaC Interim Data Observes-6-Month Median Survival Benefit – first installment

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: Video 1 Presented on OncologyTube 2023

Intra-Arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase-III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer Presented on OncologyTube 2023

RenovoGem

Intra-Arterial Gemcitabine vs IV Gemcitabine PK Substudy in Patients with Locally Advanced Pancreatic Cancer Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

RenovoRx Catheter Illustration

Incidence and Clinical Characteristics of Patients with LAPC and Mesenteric Vein Thrombosis and Current Treatment Paradigm Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

RenovoRx Catheter Illustration in all blue

Toxicity and Efficacy of Stereotactic Body Radiation Therapy vs. Intensity-Modulated Radiation Therapy for the Treatment of Locally Advanced Pancreatic Cancer in a Phase 3 Trial Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

RenovoRx Catheter Illustration

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC): A Randomized Phase 3 Multicenter Study Presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium

Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer Presented at Symposium on Clinical Interventional Oncology, September 23-25, 2022

* TAMP is currently under investigation in the United States.

RenovoRx Product Instructions For Use (IFU)

The current IFU is available at the following link:

IFU, Trans-Arterial Micro Perfusion (TAMP) RenovoCath (IFU 10004 Rev. E)

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others